Science & technology
Science & technology
Novavax creates transformational vaccines that help address some of the world’s most pressing infectious diseases.
- Our pipeline
- Matrix-M™ adjuvant
- Recombinant, protein-based nanoparticle vaccine
- Global vaccine approval/authorization map
Novavax has demonstrated its ability to quickly produce viable vaccine candidates for emerging infectious diseases such as COVID-19.
Who we are
Who we are
We are a biotechnology company committed to help address serious infectious disease globally through the discovery, development, and delivery of innovative vaccines to patients around the world.Build your future with us
Join other passionately curious people who are bringing innovative vaccines to the world
Novavax is committed to accelerating the development of new and promising vaccines by building on years of study and experience.
Our Matrix-M™ adjuvant technology
Novavax vaccines incorporate our unique Matrix-M adjuvant.
What is our Matrix-M adjuvant?
Our Matrix-M adjuvant comes from saponins, naturally occurring compounds in the bark of the Quillaja saponaria (Soapbark) tree, commonly found in Chile. Saponins have a long history of being used for their medicinal properties.1 A vaccine containing another saponin‐based adjuvant has already been approved by the US Food and Drug Administration (FDA).1,3
Novavax produces its Matrix-M adjuvant through a unique process that results in very small, spherical particles that resemble a honeycomb-like structure when viewed through a high-power microscope. Matrix-M adjuvant particles are smaller than a human hair.
Our Matrix-M adjuvant is a key element of our technology platform. When mixed with our vaccine nanoparticles, this combination of ingredients has been shown to enhance the immune system response to our vaccines, resulting in a larger, broader, and more durable response.4
How is Matrix-M made?
Soapbark trees are grown and harvested in very regulated, controlled conditions. When the trees are pruned, bark is harvested and ground into fine, pure powder. Saponins are extracted and prepared for use. Once all the processing steps are complete, the Matrix-M adjuvant is mixed with vaccine nanoparticles to produce the finished, ready-to-use vaccine.
Matrix-M adjuvant production process
Saponins, from the Quillaja saponaria tree, help generate a robust immune response.
Trees are pruned and bark is harvested
Saponins are found in the tree's bark. Bark is harvested sustainably, without felling the whole tree.
Bark is processed
Bark extract is processed into Fraction-A and Fraction-C, then freeze-dried (lyophilized). These powders contain "raw" saponin molecules.
Liquid formulation prepared
Fraction-A and Fraction-C, as liquids, are formulated with phospholipids and cholesterol, producing distinctive nanostructures.
Matrix-M adjuvant formation
Matrix-A and Matrix-C components are mixed to form Matrix-M adjuvant.
Matrix-M adiuvant is mixed with the vaccine antigen to form the final vaccine product.
The harvesting practice of Quillaja is regulated within Chile, regardless of use.
Because of the high demand for this naturally occurring product, the harvesting of saponin-producing trees is highly regulated. Significant investments have been made in forestry and production practices to ensure a sustainable supply. Under Chilean law, landowners need a special permit to cut down a Quillaja saponaria Molina tree, and are only allowed to prune up to 35% of its biomass every 5 years.5 Specially designed, low-impact harvesting methods have been developed,5 and harvesting is coupled with reforestation efforts. Saponin extraction methods are also under constant review to improve efficiency and quality, and Novavax is committed to the responsible, sustainable harvesting of saponins for use in our vaccines.
- Pulendran B, et al. Nat Rev Drug Discov. 2021;20(6):454–475.
- Bonam SR, et al. Trends Pharmacol Sci. 2017;38(9):771–793.
- FDA. Shingrix (Zoster Vaccine Recombinant, Adjuvanted) Prescribing Information. 2017.
- Keech C, et al. N Engl J Med. 2020;383(24):2320–2332.
- San Martín R, Briones R. Econ Bot. 1999;53:302–311.
A brief history of adjuvants in vaccine technology
An adjuvant is an ingredient in a vaccine that enhances the immune system’s response to that vaccine. Adjuvants help the immune system better recognize what’s in a vaccine and remember it longer, increasing the amount of time that a vaccine may offer protection.
The first adjuvant was added to a vaccine over 100 years ago, improving the strength and duration of protection.1 Adjuvants are frequently used in protein-based vaccines.1,2 Novavax has developed its own proprietary adjuvant technology, known as Matrix-M, designed to work with our nanoparticle vaccines.
Novavax' recombinant protein-based nanoparticle vaccine technology, mixed with our Matrix-M adjuvant, results in vaccine candidates that may help provide immunity against a variety of infectious diseases.
Recombinant, protein-based nanoparticle vaccine technology
Check out our pipeline to find out what we are working on and how we’re aiming to change the future of infectious diseases.